

Regimen Reference Order – HEME – givosiran

ARIA: HEME – [givosiran]

Planned Course: Once monthly (1 cycle = 28 days)

Indication for Use: Acute Hepatic Porphyria (AHP)

CVAD: Not Required

Proceed with treatment if:

- *ANC equal to or greater than $1 \times 10^9/L$ AND Platelets equal to or greater than $50 \times 10^9/L$*
 - *AST/ALT equal to or less than 3 times upper limit of normal*
 - *Total bilirubin less than or equal to 1.5 times the upper limit of normal*
- ❖ **Contact Hematologist if parameters not met**

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – HEME - givosiran

Drug	Dose	CCMB Administration Guideline
givosiran	2.5 mg/kg	Subcutaneous into the abdomen, thighs or the back of the upper arms Use 25G or 27G needle with ½" or 5/8" needle length <i>* Alert: Maximum volume at each injection site is 1.5 mL</i>
givosiran (GIVLAARI®) available dosage strength: 189 mg per 1 mL solution Classification: Non-Hazardous		

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

- CBC, serum creatinine, urea, liver enzymes and total bilirubin as per Physician Orders
- homocysteine blood level as per Physician Orders
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O2 saturation) at baseline and as clinically indicated
- Observe patient for 30 minutes after givosiran injection. Full vital signs prior to discharge

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours if needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
 - givosiran has potential for drug-drug interactions. Patients should notify clinic prior to starting any new medication
 - Advise patient to inform clinic prior to starting any over the counter medications, including vitamins, cold medications (dextromethorphan) or supplements (such as caffeine)
-

ADDITIONAL INFORMATION

- Anaphylaxis can occur with givosiran
- Elevated homocysteine blood level (greater than 15 micromol/L) may be observed in patients with Acute Hepatic Porphyrria, vitamin deficiency (B6, folate, B12) or with chronic kidney disease. Worsening hyperhomocysteinemia has been associated with givosiran
- Vitamin B6 supplementation is recommended for patients with homocysteine levels equal to or greater than 30 micromol/L